|
1
|
Samuel VT and Shulman GI: Mechanisms for
insulin resistance: common threads and missing links. Cell.
148:852–871. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kahn SE, Hull RL and Utzschneider KM:
Mechanisms linking obesity to insulin resistance and type 2
diabetes. Nature. 444:840–846. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kumar PR, Bhansali A, Ravikiran M, et al:
Utility of glycated hemoglobin in diagnosing type 2 diabetes
mellitus: a community-based study. J Clin Endocrinol Metab.
95:2832–2835. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Halperin F and Goldfine AB: Metabolic
surgery for type 2 diabetes: efficacy and risks. Curr Opin
Endocrinol Diabetes Obes. 20:98–105. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Houseknecht KL, Cole BM and Steele PJ:
Peroxisome proliferator-activated receptor gamma (PPAR gamma) and
its ligands: a review. Domest Anim Endocrinol. 22:1–23. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bajaj M, Suraamornkul S, Hardies LJ, Glass
L, Musi N and DeFronzo RA: Effects of peroxisome
proliferator-activated receptor (PPAR)-alpha and PPAR-gamma
agonists on glucose and lipid metabolism in patients with type 2
diabetes mellitus. Diabetologia. 50:1723–1731. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sharma AM and Staels B: Review: Peroxisome
proliferator-activated receptor gamma and adipose tissue -
understanding obesity-related changes in regulation of lipid and
glucose metabolism. J Clin Endocrinol Metab. 92:386–395. 2007.
View Article : Google Scholar
|
|
8
|
Shearer BG and Billin AN: The next
generation of PPAR drugs: do we have the tools to find them?
Biochim Biophys Acta. 1771:1082–1093. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Clement K, Hercberg S, Passinge B, et al:
The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and
type 2 diabetes. Int J Obes Relat Metab Disord. 24:391–393. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kadowaki T: PPAR gamma agonist and
antagonist. Nihon Yakurigaku Zasshi. 118:321–326. 2001.(In
Japanese). View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zinman B: PPAR gamma agonists in type 2
diabetes: how far have we come in ‘preventing the inevitable’? A
review of the metabolic effects of rosiglitazone. Diabetes Obes
Metab. 3(Suppl 1): S34–S43. 2001. View Article : Google Scholar
|
|
12
|
Wojtowicz AK, Szychowski KA and Kajta M:
PPAR-γ agonist GW1929 but not antagonist GW9662 reduces
TBBPA-induced neurotoxicity in primary neocortical cells. Neurotox
Res. 25:311–322. 2014. View Article : Google Scholar
|
|
13
|
de Boer RA, Martens FM, Kuipers I, Boomsma
F and Visseren FL: The effects of the PPAR-gamma agonist
pioglitazone on plasma concentrations of circulating vasoactive
factors in type II diabetes mellitus. J Hum Hypertens. 24:74–76.
2010. View Article : Google Scholar
|
|
14
|
Chawla A, Schwarz EJ, Dimaculangan DD and
Lazar MA: Peroxisome proliferator-activated receptor (PPAR) gamma:
adipose-predominant expression and induction early in adipocyte
differentiation. Endocrinology. 135:798–800. 1994.PubMed/NCBI
|
|
15
|
Huang C, Zhang Y, Gong Z, Sheng X, Li Z,
Zhang W and Qin Y: Berberine inhibits 3T3-L1 adipocyte
differentiation through the PPARgamma pathway. Biochem Biophys Res
Commun. 348:571–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sheu W, Jeng CY, Fuh M, Chen YD and Reaven
GM: Resistance to insulin-mediated glucose disposal in patients
with noninsulin-dependent diabetes mellitus in the absence of
obesity or microalbuminuria - a Clinical Research Center study. J
Clin Endocrinol Metab. 81:1156–1159. 1996.PubMed/NCBI
|
|
17
|
Chatterjee PK: Hepatic inflammation and
insulin resistance in pre-diabetes - further evidence for the
beneficial actions of PPAR-gamma agonists and a role for SOCS-3
modulation. Br J Pharmacol. 160:1889–1891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khan A, Safdar M, Ali Khan MM, Khattak KN
and Anderson RA: Cinnamon improves glucose and lipids of people
with type 2 diabetes. Diabetes Care. 26:3215–3218. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bøg-Hansen E, Lindblad U, Rånstam J,
Melander A and Rastam L: Impaired glucose metabolism and obesity in
Swedish patients with borderline isolated systolic hypertension:
Skaraborg Hypertension and Diabetes Project. Diabetes Obes Metab.
3:25–31. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hanas R and Ludvigsson J: Side effects and
indwelling times of subcutaneous catheters for insulin injections:
a new device for injecting insulin with a minimum of pain in the
treatment of insulin-dependent diabetes mellitus. Diabetes Res Clin
Pract. 10:73–83. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiang CK, Ho TI, Peng YS, et al:
Rosiglitazone in diabetes control in hemodialysis patients with and
without viral hepatitis infection: effectiveness and side effects.
Diabetes Care. 30:3–7. 2007. View Article : Google Scholar
|
|
22
|
Zhang F, Lavan BE and Gregoire FM:
Selective modulators of PPAR-gamma activity: Molecular aspects
related to obesity and side-effects. PPAR Res. 2007:326962007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Evans RM, Barish GD and Wang YX: PPARs and
the complex journey to obesity. Nat Med. 10:355–361. 2004.
View Article : Google Scholar : PubMed/NCBI
|
